US Unveils Major Science and Technology Investment; New Advances Emerge in Diabetes, Dermatology, and Cancer Treatments

This category focuses on global scientific and health advancements, which generally carry a low immediate risk. The information reported is about discoveries, trials, and approvals, not geopolitical tensions or security threats.

📌 Key developments

• US Boosts AI and Quantum Computing US President Donald Trump announced a significant $6 billion investment in science and technology, with a specific goal to develop a quantum computer for scientific discovery by 2028. This initiative, part of the "Science: A New Golden Age Summit," aims to strengthen American leadership in emerging technologies like artificial intelligence (AI) and advanced nuclear reactors. Separately, Fujitsu is partnering with the State of New Mexico to establish a new quantum computing research center, focusing on developing hardware, software, and algorithms, and building a skilled workforce in this complex field. This signifies a national and international push to advance these transformative technologies, which could lead to breakthroughs in computing power, drug discovery, and materials science. For ordinary people, quantum computing could eventually enable incredibly powerful simulations and problem-solving beyond current capabilities, though practical applications are still years away. These are investments and targets; they do not guarantee specific breakthroughs by 2028 or that the US will definitively "dominate" these fields. The Fujitsu center is a step towards research, not a guarantee of immediate commercial products.
• New Hope for Type 2 Diabetes and Weight Management Significant progress is being made in treating Type 2 Diabetes, a condition widely prevalent and feared among many, including Iranian readers. Eli Lilly recently released promising clinical trial data for a new dual-action treatment combining its drug tirzepatide (brand name Mounjaro), which is a dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, with an experimental drug called eloralintide. This combination therapy, reported in late September 2026, achieved remarkable reductions in hemoglobin A1c (a measure of average blood sugar over months) by up to 2.9 percentage points and an average total body weight loss of up to 23% in patients with Type 2 Diabetes. Additionally, a new daily oral GLP-1 pill, safiglipron, showed promising results in a trial published in Nature Medicine, cutting HbA1c by up to 1.6%. These advancements offer new and potentially more effective options for managing Type 2 Diabetes and associated weight issues, which are major health concerns globally. The combination therapy's ability to achieve substantial weight loss is particularly notable for patients who struggle with weight due to their condition. Oral medications can also be more convenient than injectables for many patients. Eli Lilly's combination therapy is still in clinical trials, meaning it is not yet approved or available in pharmacies. The oral GLP-1 pill, while promising, also needs further trials and regulatory approval. These results are from specific trials and may not be replicated in all individuals.
• Dermatology Breakthroughs for Psoriasis and Atopic Dermatitis The Fall Clinical Dermatology Conference, a major gathering for skin experts, highlighted several important advancements in 2026. New oral medications for psoriasis, a chronic autoimmune disease causing skin inflammation, are showing effectiveness comparable to biologic drugs (which are complex, protein-based drugs usually given by injection). Researchers are also exploring combinations of weight-loss drugs with treatments for psoriatic arthritis (PsA), a type of arthritis that affects some people with psoriasis. Furthermore, new three-year data for nemolizumab (brand name Nemluvio), a monoclonal antibody (a type of immune-targeting drug) that specifically blocks the signaling of interleukin-31 (IL-31), showed deep and lasting improvements in skin lesions and itch for patients aged 12 and older with atopic dermatitis (eczema), a common, chronic inflammatory skin condition. These developments offer more convenient and effective treatment options for chronic skin conditions like psoriasis and atopic dermatitis, which can significantly impact quality of life. The long-term data for nemolizumab is particularly important as it demonstrates sustained relief for a condition that often requires ongoing management. While promising, new oral psoriasis drugs are still in development and require regulatory approval. The weight-loss drug combinations are also under investigation. Nemolizumab is an approved treatment, but its long-term effectiveness in all patients is still being studied.
• FDA Approves New Colon Cancer Treatment and Fast Tracks Rare Tumor Therapy The U.S. Food and Drug Administration (FDA) approved atezolizumab (brand name Tecentriq), an immunotherapy drug, in combination with chemotherapy for the adjuvant treatment (given after initial treatment to prevent recurrence) of adults and children aged 2 and older with stage III mismatch repair deficient (dMMR) colon cancer. This type of colon cancer has specific genetic changes that make it responsive to certain immunotherapies. In other cancer news, Perspective Therapeutics received Fast Track Designation from the FDA for [212Pb]PSV359, an investigational alpha-particle therapy (a type of radiation therapy that uses alpha particles to target cancer cells) for adult patients with locally advanced unresectable (cannot be surgically removed) and/or metastatic (spread to other parts of the body) fibroblast activation protein (FAP)-positive solitary fibrous tumors (SFTs), a rare form of cancer. The colon cancer approval provides a new, targeted treatment option for patients after surgery, aiming to reduce recurrence. Fast Track Designation for [212Pb]PSV359 means the FDA will expedite its review process, potentially bringing a much-needed treatment to patients with a rare and aggressive cancer that currently has limited options. While approved, the colon cancer treatment's long-term impact on overall survival continues to be monitored. Fast Track Designation does not guarantee approval or that the rare cancer therapy will be safe or effective for all patients; it only speeds up the review process.
• AI Accelerates Materials Discovery NTT, a Japanese telecommunications company, is pioneering an "AI for Science" approach to speed up the discovery of new materials. Their research, published today, October 9, 2026, focuses on using AI to explore experimental possibilities and identify patterns in data that human researchers might miss. For example, they successfully used AI to find the optimal conditions for producing single-crystal β-Ga₂O₃ films, a material with potential applications in semiconductors and optics. This approach could drastically reduce the time and cost involved in developing advanced materials needed for everything from faster electronics to more efficient energy solutions. It allows scientists to focus on understanding the underlying principles rather than exhaustive trial-and-error. This is a proof-of-concept for the "AI for Science" method in a specific materials science problem. It does not mean AI can solve all materials science challenges or that it will immediately lead to commercially available products. The human element of understanding and applying the AI's findings remains crucial.
• New Non-Hormonal Hair Loss Treatments in Development While no new hair loss breakthroughs were announced today, 2026 has seen significant progress in developing non-hormonal treatments, a welcome development for many, including Iranian readers concerned about hair loss. Clascoterone, a topical androgen receptor inhibitor (a drug applied to the skin that blocks the effects of hormones like dihydrotestosterone, or DHT, locally without affecting the whole body), completed two pivotal Phase 3 trials in December 2025. Results showed up to a 539% relative improvement in hair count versus placebo. Cosmo Pharmaceuticals plans to submit it for approval to the FDA (U.S. Food and Drug Administration) and EMA (European Medicines Agency) in 2026. Another promising compound, PP405 from Pelage Pharmaceuticals, targets the reactivation of dormant hair follicle stem cells (specialized cells that can develop into different cell types, in this case, hair cells). In Phase 2a trials, 31% of patients with higher hair loss saw more than a 20% increase in hair density, with Phase 3 studies planned for 2026. These represent new approaches to treating androgenetic alopecia (pattern baldness), a common and often distressing condition. Clascoterone offers a non-systemic option, which is particularly important for women who may not be suitable for existing hormonal treatments. PP405's focus on reactivating dormant stem cells suggests that hair follicles might not be permanently lost but can be "woken up." Clascoterone is awaiting regulatory approval and is not yet available. PP405 is still in earlier stages of development with Phase 3 trials planned, meaning it is years away from potential availability and its long-term safety and efficacy are still being investigated. These results are from specific trials and may not be universally applicable.

💡 Why it matters

These developments are critical for policymakers and analysts as they highlight areas of significant investment and rapid technological advancement. The push in AI and quantum computing has national security and economic implications, while breakthroughs in health directly impact public well-being, healthcare costs, and global health equity. Understanding the stage and timeline of these innovations is crucial for strategic planning and resource allocation.

🎭 People in the news

• Donald Trump — US President, announced a $6 billion science and technology initiative and a 2028 target for quantum computing.
• Shubham Pandey — Founder and CEO of Alpha1 AI, attended the White House's "Science: A New Golden Age Summit" to discuss AI-powered learning and problem-solving.
• Annet Kirabo — Professor of medicine in the division of genetic medicine and clinical pharmacology at Vanderbilt Health, will receive the 2026 Joseph A. Vita Award for her discoveries related to immune cell activation and hypertension.

👀 What to watch

• Further announcements from the Heart Failure Society of America (HFSA) Annual Scientific Meeting (October 9-12, 2026) regarding late-breaking clinical research in heart failure and cardiac amyloidosis.
• Updates from the Fall Clinical Dermatology Conference (October 8-11, 2026) on emerging therapies and diagnostic approaches in dermatology.
• Any further details or reactions to the US President's science and technology investment announcements.